Recent NRG Oncology clinical trials have yielded significant findings across multiple cancer types. The NRG-BN001 trial demonstrated enhanced survival in glioblastoma patients treated with proton therapy, with progression to Phase III. Another study on radiation therapy frequency in limited-stage small cell lung cancer revealed quality of life improvements for twice-daily dosing versus once-daily. Additional NRG trials highlighted improved outcomes in stage III non-small cell lung cancer through neoadjuvant chemoimmunotherapy and surgery, and better bowel health quality of life with stereotactic body radiation therapy compared to conventional approaches.